AcuCort AB (XSAT:ACUC) EBITDA Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:ACUC AcuCort AB XSAT:ACUC
32 GF Score
Price kr0.64
! 2 Warning Signs
View Full Analysis

What is AcuCort AB EBITDA Margin %?

AcuCort AB XSAT:ACUC -0.31% 32 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates XSAT:ACUC with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 961 Drug Manufacturers companies, AcuCort AB ranks worse than 98.02% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. AcuCort AB's EBITDA for the three months ended in Mar. 2026 was kr-4.66 Mil. AcuCort AB's Revenue for the three months ended in Mar. 2026 was kr0.00 Mil. Therefore, AcuCort AB's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

AcuCort AB  (XSAT:ACUC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

AcuCort AB EBITDA Margin % Related Terms

AcuCort AB EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for AcuCort AB's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AcuCort AB EBITDA Margin % Chart

AcuCort AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -2,009.19 -2,583.41

AcuCort AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -3,375.93 -624.95 0.00 0.00

XSAT:ACUC vs ZTS, UTHR: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, AcuCort AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AcuCort AB EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AcuCort AB's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where AcuCort AB's EBITDA Margin % falls into.


XSAT:ACUC
32GF Score
AcuCort AB XSAT:ACUC
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AcuCort AB EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

AcuCort AB's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-17.748/0.687
=-2,583.41 %

AcuCort AB's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-4.662/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
AcuCort AB (XSAT:ACUC) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AcuCort AB and its competitors. According to the industry distribution chart, AcuCort AB ranks #942 out of 961 companies in the Drug Manufacturers industry, placing it in the top 98%.
Is AcuCort AB's EBITDA Margin % too high?
AcuCort AB's current EBITDA Margin % is 0.00%. Based on the distribution chart, AcuCort AB ranks #942 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AcuCort AB has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does AcuCort AB's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AcuCort AB ranks #942 out of 961 companies for EBITDA Margin %. This places AcuCort AB in the lower half of its industry. The industry median EBITDA Margin % is 12.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AcuCort AB and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AcuCort AB's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AcuCort AB stock overvalued right now?
AcuCort AB (XSAT:ACUC) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. AcuCort AB's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For AcuCort AB (XSAT:ACUC), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AcuCort AB Business Description

Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
AcuCort AB is an innovative biotechnology company that identifies, develops and commercializes smart drugs that meet the patient's needs for a user-friendly and effective treatment.
32GF Score

Get the complete analysis for XSAT:ACUC

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.64
Price